Adjuvant Therapy for Pancreatic Cancer View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2012-11-06

AUTHORS

Asma Sultana , Trevor Cox , Paula Ghaneh , John P. Neoptolemos

ABSTRACT

Pancreatic cancer is a challenging malignancy to treat, as less than one-fifth of diagnosed cases are resectable, surgery is complex and postoperative recovery slow, treated patients tend to relapse and overall survival rates are low. It is one of the leading causes of cancer-related mortality. Adjuvant therapy has been employed in resectable disease, to target micrometastases and improve prognosis. Chemotherapy, chemoradiotherapy (chemoRT) and chemoradiotherapy (chemoRT) followed on by chemotherapy have been evaluated in randomised controlled trials. The European Study Group for Pancreatic Cancer (ESPAC)-1 and CONKO-001 trials clearly established the survival advantage of adjuvant chemotherapy with 5 fluorouracil (5FU) plus folinic acid and gemcitabine respectively over no chemotherapy. The ESPAC-3 (version 2) trial demonstrated equivalence between 5FU plus folinic acid and gemcitabine in terms of survival parameters, though gemcitabine had a better toxicity profile. The results of these key studies, together with smaller ones have been subjected to meta-analyses, with confirmation of improved survival with adjuvant systemic chemotherapy. The EORTC-40891 and ESPAC-1 trials found no survival advantage with adjuvant chemoRT compared to observation, and this has been reflected in a subsequent meta-analysis. The popularisation of chemoRT, with follow on chemotherapy (versus observation) was based on the small underpowered GITSG trial. The ESPAC-1 trial was unable to find a survival benefit for chemoRT, with follow on chemotherapy compared to observation. The RTOG-9704 trial assessed chemoRT with follow on chemotherapy in both arms and found no difference between survival in the gemcitabine and 5FU arms. There has never been a published head-to-head randomised comparison of adjuvant chemotherapy to chemoRT, with follow on chemotherapy. Ongoing randomised trials are looking into adjuvant combination chemotherapy, chemotherapy with follow on chemoRT, and neoadjuvant therapy. Novel agents continue to be assessed in early phase trials with a major emphasis on predictive and prognostic biomarkers. Based on the available evidence, adjuvant chemotherapy with gemcitabine or 5FU/folinic acid is the current recommended gold standard in the management of resected pancreatic cancer. More... »

PAGES

65-88

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-642-31629-6_5

DOI

http://dx.doi.org/10.1007/978-3-642-31629-6_5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1011326130

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23129367


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The Liverpool Cancer Research UK Trials Unit, and the Department of Molecular and Clinical Cancer Medicine Centre, University of Liverpool, Liverpool Cancer Research Centre, Royal Liverpool University Hospital, Daulby Street, L69 3GA, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/grid.415970.e", 
          "name": [
            "The Liverpool Cancer Research UK Trials Unit, and the Department of Molecular and Clinical Cancer Medicine Centre, University of Liverpool, Liverpool Cancer Research Centre, Royal Liverpool University Hospital, Daulby Street, L69 3GA, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sultana", 
        "givenName": "Asma", 
        "id": "sg:person.01246775112.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246775112.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Liverpool Cancer Research UK Trials Unit, and the Department of Molecular and Clinical Cancer Medicine Centre, University of Liverpool, Liverpool Cancer Research Centre, Royal Liverpool University Hospital, Daulby Street, L69 3GA, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/grid.415970.e", 
          "name": [
            "The Liverpool Cancer Research UK Trials Unit, and the Department of Molecular and Clinical Cancer Medicine Centre, University of Liverpool, Liverpool Cancer Research Centre, Royal Liverpool University Hospital, Daulby Street, L69 3GA, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cox", 
        "givenName": "Trevor", 
        "id": "sg:person.01074047400.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074047400.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Liverpool Cancer Research UK Trials Unit, and the Department of Molecular and Clinical Cancer Medicine Centre, University of Liverpool, Liverpool Cancer Research Centre, Royal Liverpool University Hospital, Daulby Street, L69 3GA, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/grid.415970.e", 
          "name": [
            "The Liverpool Cancer Research UK Trials Unit, and the Department of Molecular and Clinical Cancer Medicine Centre, University of Liverpool, Liverpool Cancer Research Centre, Royal Liverpool University Hospital, Daulby Street, L69 3GA, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghaneh", 
        "givenName": "Paula", 
        "id": "sg:person.07372440237.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Liverpool Cancer Research UK Trials Unit, and the Department of Molecular and Clinical Cancer Medicine Centre, University of Liverpool, Liverpool Cancer Research Centre, Royal Liverpool University Hospital, Daulby Street, L69 3GA, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/grid.415970.e", 
          "name": [
            "The Liverpool Cancer Research UK Trials Unit, and the Department of Molecular and Clinical Cancer Medicine Centre, University of Liverpool, Liverpool Cancer Research Centre, Royal Liverpool University Hospital, Daulby Street, L69 3GA, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neoptolemos", 
        "givenName": "John P.", 
        "id": "sg:person.0750565077.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2012-11-06", 
    "datePublishedReg": "2012-11-06", 
    "description": "Pancreatic cancer is a challenging malignancy to treat, as less than one-fifth of diagnosed cases are resectable, surgery is complex and postoperative recovery slow, treated patients tend to relapse and overall survival rates are low. It is one of the leading causes of cancer-related mortality. Adjuvant therapy has been employed in resectable disease, to target micrometastases and improve prognosis. Chemotherapy, chemoradiotherapy (chemoRT) and chemoradiotherapy (chemoRT) followed on by chemotherapy have been evaluated in randomised controlled trials. The European Study Group for Pancreatic Cancer (ESPAC)-1 and CONKO-001 trials clearly established the survival advantage of adjuvant chemotherapy with 5 fluorouracil (5FU) plus folinic acid and gemcitabine respectively over no chemotherapy. The ESPAC-3 (version 2) trial demonstrated equivalence between 5FU plus folinic acid and gemcitabine in terms of survival parameters, though gemcitabine had a better toxicity profile. The results of these key studies, together with smaller ones have been subjected to meta-analyses, with confirmation of improved survival with adjuvant systemic chemotherapy. The EORTC-40891 and ESPAC-1 trials found no survival advantage with adjuvant chemoRT compared to observation, and this has been reflected in a subsequent meta-analysis. The popularisation of chemoRT, with follow on chemotherapy (versus observation) was based on the small underpowered GITSG trial. The ESPAC-1 trial was unable to find a survival benefit for chemoRT, with follow on chemotherapy compared to observation. The RTOG-9704 trial assessed chemoRT with follow on chemotherapy in both arms and found no difference between survival in the gemcitabine and 5FU arms. There has never been a published head-to-head randomised comparison of adjuvant chemotherapy to chemoRT, with follow on chemotherapy. Ongoing randomised trials are looking into adjuvant combination chemotherapy, chemotherapy with follow on chemoRT, and neoadjuvant therapy. Novel agents continue to be assessed in early phase trials with a major emphasis on predictive and prognostic biomarkers. Based on the available evidence, adjuvant chemotherapy with gemcitabine or 5FU/folinic acid is the current recommended gold standard in the management of resected pancreatic cancer.", 
    "editor": [
      {
        "familyName": "Otto", 
        "givenName": "Florian", 
        "type": "Person"
      }, 
      {
        "familyName": "Lutz", 
        "givenName": "Manfred P.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-642-31629-6_5", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-642-31628-9", 
        "978-3-642-31629-6"
      ], 
      "name": "Early Gastrointestinal Cancers", 
      "type": "Book"
    }, 
    "keywords": [
      "ESPAC-1 trial", 
      "pancreatic cancer", 
      "adjuvant chemotherapy", 
      "folinic acid", 
      "adjuvant therapy", 
      "survival advantage", 
      "CONKO-001 trial", 
      "ESPAC-3 trial", 
      "adjuvant systemic chemotherapy", 
      "adjuvant combination chemotherapy", 
      "overall survival rate", 
      "cancer-related mortality", 
      "better toxicity profile", 
      "early phase trials", 
      "European Study Group", 
      "resectable disease", 
      "adjuvant chemoRT", 
      "systemic chemotherapy", 
      "neoadjuvant therapy", 
      "postoperative recovery", 
      "survival benefit", 
      "combination chemotherapy", 
      "challenging malignancy", 
      "chemoRT", 
      "phase trials", 
      "novel agents", 
      "prognostic biomarker", 
      "study group", 
      "toxicity profile", 
      "chemotherapy", 
      "gemcitabine", 
      "survival rate", 
      "follow", 
      "cancer", 
      "available evidence", 
      "trials", 
      "therapy", 
      "gold standard", 
      "chemoradiotherapy", 
      "survival parameters", 
      "one-fifth", 
      "survival", 
      "key studies", 
      "micrometastases", 
      "RTOG", 
      "surgery", 
      "patients", 
      "fluorouracil", 
      "prognosis", 
      "malignancy", 
      "arm", 
      "mortality", 
      "head", 
      "disease", 
      "biomarkers", 
      "cause", 
      "acid", 
      "group", 
      "confirmation", 
      "agents", 
      "evidence", 
      "major emphasis", 
      "management", 
      "differences", 
      "cases", 
      "recovery", 
      "study", 
      "benefits", 
      "rate", 
      "profile", 
      "observations", 
      "standards", 
      "comparison", 
      "results", 
      "emphasis", 
      "advantages", 
      "smaller ones", 
      "parameters", 
      "terms", 
      "one", 
      "equivalence", 
      "popularisation"
    ], 
    "name": "Adjuvant Therapy for Pancreatic Cancer", 
    "pagination": "65-88", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1011326130"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-642-31629-6_5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23129367"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-642-31629-6_5", 
      "https://app.dimensions.ai/details/publication/pub.1011326130"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_374.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-642-31629-6_5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-31629-6_5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-31629-6_5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-31629-6_5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-31629-6_5'


 

This table displays all metadata directly associated to this object as RDF triples.

191 TRIPLES      22 PREDICATES      112 URIs      105 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-642-31629-6_5 schema:about N662fef990dc54148acd26b1bf3470098
2 N77ee373f68134fd58b0ad7f96089c9ab
3 Nae4a0dc7caf34850b9caf0f7b766163f
4 Ne586343a2f9b482d930419d343ddca65
5 Nfae0b9c7fc374ae982a74f42ff100b27
6 anzsrc-for:11
7 anzsrc-for:1112
8 schema:author N3312c7f75793442da716687a762bb822
9 schema:datePublished 2012-11-06
10 schema:datePublishedReg 2012-11-06
11 schema:description Pancreatic cancer is a challenging malignancy to treat, as less than one-fifth of diagnosed cases are resectable, surgery is complex and postoperative recovery slow, treated patients tend to relapse and overall survival rates are low. It is one of the leading causes of cancer-related mortality. Adjuvant therapy has been employed in resectable disease, to target micrometastases and improve prognosis. Chemotherapy, chemoradiotherapy (chemoRT) and chemoradiotherapy (chemoRT) followed on by chemotherapy have been evaluated in randomised controlled trials. The European Study Group for Pancreatic Cancer (ESPAC)-1 and CONKO-001 trials clearly established the survival advantage of adjuvant chemotherapy with 5 fluorouracil (5FU) plus folinic acid and gemcitabine respectively over no chemotherapy. The ESPAC-3 (version 2) trial demonstrated equivalence between 5FU plus folinic acid and gemcitabine in terms of survival parameters, though gemcitabine had a better toxicity profile. The results of these key studies, together with smaller ones have been subjected to meta-analyses, with confirmation of improved survival with adjuvant systemic chemotherapy. The EORTC-40891 and ESPAC-1 trials found no survival advantage with adjuvant chemoRT compared to observation, and this has been reflected in a subsequent meta-analysis. The popularisation of chemoRT, with follow on chemotherapy (versus observation) was based on the small underpowered GITSG trial. The ESPAC-1 trial was unable to find a survival benefit for chemoRT, with follow on chemotherapy compared to observation. The RTOG-9704 trial assessed chemoRT with follow on chemotherapy in both arms and found no difference between survival in the gemcitabine and 5FU arms. There has never been a published head-to-head randomised comparison of adjuvant chemotherapy to chemoRT, with follow on chemotherapy. Ongoing randomised trials are looking into adjuvant combination chemotherapy, chemotherapy with follow on chemoRT, and neoadjuvant therapy. Novel agents continue to be assessed in early phase trials with a major emphasis on predictive and prognostic biomarkers. Based on the available evidence, adjuvant chemotherapy with gemcitabine or 5FU/folinic acid is the current recommended gold standard in the management of resected pancreatic cancer.
12 schema:editor N72ddc40e5fb5495ea31bbae5d1fdc173
13 schema:genre chapter
14 schema:isAccessibleForFree false
15 schema:isPartOf Nfb464653f4c54147af2754e6d5306f0a
16 schema:keywords CONKO-001 trial
17 ESPAC-1 trial
18 ESPAC-3 trial
19 European Study Group
20 RTOG
21 acid
22 adjuvant chemoRT
23 adjuvant chemotherapy
24 adjuvant combination chemotherapy
25 adjuvant systemic chemotherapy
26 adjuvant therapy
27 advantages
28 agents
29 arm
30 available evidence
31 benefits
32 better toxicity profile
33 biomarkers
34 cancer
35 cancer-related mortality
36 cases
37 cause
38 challenging malignancy
39 chemoRT
40 chemoradiotherapy
41 chemotherapy
42 combination chemotherapy
43 comparison
44 confirmation
45 differences
46 disease
47 early phase trials
48 emphasis
49 equivalence
50 evidence
51 fluorouracil
52 folinic acid
53 follow
54 gemcitabine
55 gold standard
56 group
57 head
58 key studies
59 major emphasis
60 malignancy
61 management
62 micrometastases
63 mortality
64 neoadjuvant therapy
65 novel agents
66 observations
67 one
68 one-fifth
69 overall survival rate
70 pancreatic cancer
71 parameters
72 patients
73 phase trials
74 popularisation
75 postoperative recovery
76 profile
77 prognosis
78 prognostic biomarker
79 rate
80 recovery
81 resectable disease
82 results
83 smaller ones
84 standards
85 study
86 study group
87 surgery
88 survival
89 survival advantage
90 survival benefit
91 survival parameters
92 survival rate
93 systemic chemotherapy
94 terms
95 therapy
96 toxicity profile
97 trials
98 schema:name Adjuvant Therapy for Pancreatic Cancer
99 schema:pagination 65-88
100 schema:productId N7d89493924204c25a524365cd497d472
101 Nd2e231d676be4da0830bc17a5ed51c57
102 Nde8e77b8c9b64a08aac7d1c3a9017b70
103 schema:publisher Ne687daca43364352a8ff1beef4d8cd3c
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011326130
105 https://doi.org/10.1007/978-3-642-31629-6_5
106 schema:sdDatePublished 2022-09-02T16:16
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher N25d9381f3112414ab094aae4b9b10182
109 schema:url https://doi.org/10.1007/978-3-642-31629-6_5
110 sgo:license sg:explorer/license/
111 sgo:sdDataset chapters
112 rdf:type schema:Chapter
113 N0e078ab2c3304d9cb0f8ee4ed6a75225 rdf:first N370750760240411db767e7c6a330adf4
114 rdf:rest rdf:nil
115 N25d9381f3112414ab094aae4b9b10182 schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 N3312c7f75793442da716687a762bb822 rdf:first sg:person.01246775112.38
118 rdf:rest Ne2bf2a65ef0b4748a7c57762e272d69f
119 N370750760240411db767e7c6a330adf4 schema:familyName Lutz
120 schema:givenName Manfred P.
121 rdf:type schema:Person
122 N662fef990dc54148acd26b1bf3470098 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Chemotherapy, Adjuvant
124 rdf:type schema:DefinedTerm
125 N72ddc40e5fb5495ea31bbae5d1fdc173 rdf:first Na10a9e0620ec42b894a72bdac376d7a4
126 rdf:rest N0e078ab2c3304d9cb0f8ee4ed6a75225
127 N77ee373f68134fd58b0ad7f96089c9ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Radiotherapy, Adjuvant
129 rdf:type schema:DefinedTerm
130 N7d89493924204c25a524365cd497d472 schema:name doi
131 schema:value 10.1007/978-3-642-31629-6_5
132 rdf:type schema:PropertyValue
133 N8479455ccb8a4e55b83478d6842ec703 rdf:first sg:person.07372440237.86
134 rdf:rest Ndd0f63fe9b37448799071aa127b050df
135 Na10a9e0620ec42b894a72bdac376d7a4 schema:familyName Otto
136 schema:givenName Florian
137 rdf:type schema:Person
138 Nae4a0dc7caf34850b9caf0f7b766163f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Humans
140 rdf:type schema:DefinedTerm
141 Nd2e231d676be4da0830bc17a5ed51c57 schema:name dimensions_id
142 schema:value pub.1011326130
143 rdf:type schema:PropertyValue
144 Ndd0f63fe9b37448799071aa127b050df rdf:first sg:person.0750565077.18
145 rdf:rest rdf:nil
146 Nde8e77b8c9b64a08aac7d1c3a9017b70 schema:name pubmed_id
147 schema:value 23129367
148 rdf:type schema:PropertyValue
149 Ne2bf2a65ef0b4748a7c57762e272d69f rdf:first sg:person.01074047400.51
150 rdf:rest N8479455ccb8a4e55b83478d6842ec703
151 Ne586343a2f9b482d930419d343ddca65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Pancreatic Neoplasms
153 rdf:type schema:DefinedTerm
154 Ne687daca43364352a8ff1beef4d8cd3c schema:name Springer Nature
155 rdf:type schema:Organisation
156 Nfae0b9c7fc374ae982a74f42ff100b27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Clinical Trials as Topic
158 rdf:type schema:DefinedTerm
159 Nfb464653f4c54147af2754e6d5306f0a schema:isbn 978-3-642-31628-9
160 978-3-642-31629-6
161 schema:name Early Gastrointestinal Cancers
162 rdf:type schema:Book
163 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
164 schema:name Medical and Health Sciences
165 rdf:type schema:DefinedTerm
166 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
167 schema:name Oncology and Carcinogenesis
168 rdf:type schema:DefinedTerm
169 sg:person.01074047400.51 schema:affiliation grid-institutes:grid.415970.e
170 schema:familyName Cox
171 schema:givenName Trevor
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074047400.51
173 rdf:type schema:Person
174 sg:person.01246775112.38 schema:affiliation grid-institutes:grid.415970.e
175 schema:familyName Sultana
176 schema:givenName Asma
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246775112.38
178 rdf:type schema:Person
179 sg:person.07372440237.86 schema:affiliation grid-institutes:grid.415970.e
180 schema:familyName Ghaneh
181 schema:givenName Paula
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86
183 rdf:type schema:Person
184 sg:person.0750565077.18 schema:affiliation grid-institutes:grid.415970.e
185 schema:familyName Neoptolemos
186 schema:givenName John P.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18
188 rdf:type schema:Person
189 grid-institutes:grid.415970.e schema:alternateName The Liverpool Cancer Research UK Trials Unit, and the Department of Molecular and Clinical Cancer Medicine Centre, University of Liverpool, Liverpool Cancer Research Centre, Royal Liverpool University Hospital, Daulby Street, L69 3GA, Liverpool, UK
190 schema:name The Liverpool Cancer Research UK Trials Unit, and the Department of Molecular and Clinical Cancer Medicine Centre, University of Liverpool, Liverpool Cancer Research Centre, Royal Liverpool University Hospital, Daulby Street, L69 3GA, Liverpool, UK
191 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...